For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease ...

The vaccine would train the immune system to fight cancer-causing mutations, according to new research from UCLA Health.

Phase 1 trial of a pancreatic cancer vaccine targeting mutant KRAS shows strong immune responses, extended survival, and ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

A new study reveals promising results for a vaccine targeting colorectal and pancreatic cancers. Researchers from the ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in ...

Researchers found patients with pancreatic cancer and bowel cancer survived more than two years after receiving the vaccine ...